A procedure that allows the improved extraction of the dose information based on the multicolor scanning of the radiochromic film is presented. The basic principle is the determination of the dose values from each color channel of the digital film image in RGB format by applying a nonlinear calibration function. The best estimate of the dose is then a weighted mean of the dose values derived from each color channel. The weighting factors are determined in such a way that the noise in the two-dimensional dose profile is at the minimum. The calculation of the weighting factors is presented; they are chosen to be proportional to the signal-to-noise ratio, Si/v(i)2, in all three color channels, i=red, green, or blue. The data reduction can be fully computerized, including the "cleaning" of the digital image from dust and scratches. It is highly reproducible, which is important for quality assurance, and easy to use. Our novel evaluation procedure combines the good response in the low dose range of the red color with the extended dose range of the blue and green color channels (response up to 10,000 Gy), making use of one single, steady evaluation function. Therefore, a smooth evaluation is possible in a wide dose range. For the interpretation of measurements with the radiochromic films the spatial inhomogeneity of the film's response to ionizing radiation is very important. Investigations on both film types, HS and MD55-2, as well as on the new EBT film have been carried out.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1118/1.2357019 | DOI Listing |
J Clin Oncol
January 2025
Center for Cell Engineering, Sloan Kettering Institute, New York, NY.
Purpose: We designed a CD19-targeted chimeric antigen receptor (CAR) comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3ζ and 4-1BB/CD3ζ CARs. Preclinical data demonstrated that 1XX CARs generated potent effector function without undermining T-cell persistence. We hypothesized that 1XX CAR T cells may be effective at low doses and elicit minimal toxicities.
View Article and Find Full Text PDFInfect Dis Ther
January 2025
Vaccine Research and Development, Pfizer R&D UK Ltd, Marlow, UK.
Introduction: Infants and young children typically have the highest age-related risk of invasive meningococcal disease. The immunogenicity and safety of a single primary dose and a booster of a meningococcal A/C/W/Y tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix) in infants were evaluated.
Methods: In this phase 3b, open-label, single-arm study, healthy 3-month-old infants received a single Nimenrix dose followed by a booster at age 12 months (1 + 1 series).
Invest New Drugs
January 2025
Department of Internal Medicine, Jilin Cancer Hospital, Changchun, China.
Background: Immune checkpoint inhibitors (ICIs) combined with anti-vascular endothelial growth factor (VEGF) have been the standard first-line treatment of hepatocellular carcinoma (HCC). However, the efficacy of this combination in post-line treatment is still unknown. This study aimed to evaluate the efficacy and safety of the combination of anti-PD-L1 envafolimab and novel humanized anti-VEGF suvemcitug as second-line treatment for patients with HCC.
View Article and Find Full Text PDFBackground: Radio-chemotherapy remains the mainstay of glioblastoma first-line treatment after extended surgery, but the prognosis is still poor. PARP inhibitors like olaparib may improve glioblastoma outcomes. We implemented a phase 1-2a trial to assess the safety and efficacy of olaparib combined with standard radio-chemotherapy as a first-line treatment in unresected glioblastoma patients.
View Article and Find Full Text PDFClin Toxicol (Phila)
January 2025
National Poisons Information Service, Cardiff Unit, University Hospital Llandough, Penarth, UK.
Introduction: Ibogaine is a psychoactive alkaloid derived from the root bark of the West African shrub . It is not licensed in the United Kingdom but is used by individuals to alleviate drug or alcohol use.
Methods: A retrospective analysis of telephone enquiries involving ibogaine between 1 January 2012 and 31 December 2022 to the United Kingdom National Poisons Information Service was performed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!